Best ASX Health Care Stocks to Invest In
AI-curated Health Care stock ideas for the Australian (ASX) market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
20 picks · prices as of close 2026-10-27
CSL Limited
Institutional overweighting, sector leadership, supportive pipeline deal, and improving healthcare momentum support recovery potential.
▸Institutional accumulation and Morgans buy rating with $187.71 target
Pro Medicus Limited
Recurring imaging-software growth, fresh US contracts, and strong momentum support continued premium earnings compounding.
▸Morgans upgraded to buy after US contract wins
Cochlear Limited
Global hearing-device leadership, resilient demand, and sector rotation into high-quality franchises support further upside.
▸Positive sector momentum and institutional preference for quality healthcare
ResMed Inc.
Strong broker support, durable sleep-apnoea demand, and positive earnings expectations create attractive forward value.
▸Majority broker buy ratings and 18% average target upside
Fisher & Paykel Healthcare Corporation Limited
RBC overweight stance, recurring respiratory demand, and premium international franchise support sustained growth.
▸RBC overweight call and positive sector earnings outlook
Ramsay Health Care Limited
Defensive hospital demand and improving earnings expectations offer re-rating potential despite recent share strength.
▸Goldman Sachs upgraded shares and RBC remains overweight
Nanosonics Limited
RBC endorsement, recurring procedure demand, and healthcare-sector re-rating provide attractive medium-term support.
▸RBC overweight recommendation amid improving sector earnings
Sigma Healthcare Limited
Strong trading update, Chemist Warehouse exposure, and weight-loss-drug sales provide near-term earnings catalysts.
▸Morgans buy rating and positive weight-loss-drug sales update
EBOS Group Limited
Defensive healthcare distribution, expected positive trading update, and reliable cash generation support valuation resilience.
▸Expected positive trading update and defensive healthcare exposure
Cogstate Limited
Digital cognitive-testing growth and broker support offer speculative upside as clinical adoption expands.
▸Morgans buy rating with $4.07 target
Telix Pharmaceuticals Limited
Commercial radiopharmaceutical growth and positive analyst coverage support continued pipeline-driven appreciation.
▸Analyst buy rating despite recent weakness
Sonic Healthcare Limited
Defensive diagnostics franchise offers recovery value, although reduced broker target limits near-term conviction.
▸Low valuation after substantial target reduction and mixed analyst sentiment
Imricor Medical Systems, Inc.
Potential regulatory and clinical milestones could accelerate adoption of its cardiac imaging technology.
▸Upcoming clinical and regulatory milestones
Vitrafy Life Sciences Limited
Clinical and regulatory progress could unlock commercial partnerships and improve investor sentiment.
▸Expected regulatory and clinical milestone catalysts
Tetratherix Limited
Biomaterials pipeline milestones and healthcare-sector rotation provide speculative catalyst-driven upside.
▸Upcoming clinical and regulatory milestones
BlinkLab Limited
Digital diagnostics development and anticipated milestones offer high-risk, high-upside optionality.
▸Expected clinical and regulatory milestone catalysts
Neurizon Therapeutics Limited
Positive FDA pathway feedback materially improves development visibility for its ALS candidate.
▸FDA feedback supported speculative buy recommendation
Saluda Medical, Inc.
Broker-backed turnaround potential and consumer healthcare exposure provide asymmetric speculative upside.
▸Morgans speculative buy rating with $2.17 target
EBR Systems, Inc.
Wireless cardiac pacing opportunity remains significant, but weaker implant data warrants cautious positioning.
▸Speculative buy retained after target reduction on missed implants
Mesoblast Limited
Regenerative-medicine commercialization potential offers upside, but clinical and regulatory execution risk remains elevated.
▸Pipeline catalyst potential without verified current upgrade